At the news
? BULLISHIMPACT 7/10 8-K filed Aug 10, 2026 at 16:17 ET
Rocket Pharmaceuticals reported Q2 2026 GAAP net income of $123.2M ($1.09 basic EPS), driven by a $178.2M gain from the sale of its Priority Review Voucher (PRV), compared to a net loss of $68.9M in Q2 2025. Operating loss improved to $46.9M from $71.1M on lower R&D and G&A expenses. The company ended the quarter with $283.7M in cash, extending runway into Q2 2028, and reported positive safety data from the first three Danon disease patients in the pivotal Phase 2 trial of RP-A501.
- GAAP net income of $123.2M in Q2 2026 vs net loss of $68.9M in Q2 2025, primarily due to $178.2M gain from PRV sale.
- Cash, cash equivalents, and investments of $283.7M as of June 30, 2026, up from $188.9M at Dec 31, 2025, extending runway into Q2 2028.
- All three initial patients in the pivotal Phase 2 trial of RP-A501 for Danon disease completed the safety observation period with no TMA, capillary leak syndrome, or other significant safety concerns.
- KRESLADI (marnetegragene autotemcel) received FDA accelerated approval for severe LAD-I; commercial availability and patient onboarding expected to begin in Q4 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access